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Abstract
Background: Understanding the implementation of 2013 World Health Organization (WHO) consolidated guidelines
on the use of antiretroviral drugs for treating and preventing HIV infection at the facility level provides important
lessons for the roll-out of future HIV policies.
Methods: A national policy review was conducted in six sub-Saharan African countries to map the inclusion of the
2013 WHO HIV treatment recommendations. Twenty indicators of policy adoption were selected to measure ART
access (n = 12) and retention (n = 8). Two sequential cross-sectional surveys were conducted in facilities between
2013/2015 (round 1) and 2015/2016 (round 2) from ten health and demographic surveillance sites in Kenya,
Malawi, South Africa, Tanzania, Uganda and Zimbabwe. Using standardised questionnaires, facility managers were
interviewed. Descriptive analyses were used to assess the change in the proportion of facilities that implemented
these policy indicators between rounds.
Results: Although, expansion of ART access was explicitly stated in all countries’ policies, most lacked policies that
enhanced retention. Overall, 145 facilities were included in both rounds. The proportion of facilities that initiated ART at
CD4 counts of 500 or less cells/μL increased between round 1 and 2 from 12 to 68%, and facilities initiating patients on
2013 WHO recommended ART regimen increased from 42 to 87%. There were no changes in the proportion of
facilities reporting stock-outs of first-line ART in the past year (18 to 11%) nor in the provision of three-month supply of
ART (43 to 38%). None of the facilities provided community-based ART delivery.
Conclusion: The increase in ART initiation CD4 threshold in most countries, and substantial improvements made in the
provision of WHO recommended first-line ART regimens demonstrates that rapid adoption of WHO recommendations
is possible. However, improved logistics and resources and/or changes in policy are required to further minimise ART
stock-outs and allow lay cadres to dispense ART in the community. Increased efforts are needed to offer longer
durations between clinic visits, a strategy purported to improve retention. These changes will be important as countries
move to implement the revised 2015 WHO guidelines to initiate all HIV positive people onto ART regardless of their
immune status.
Keywords: WHO guidelines, Policy review, Health facility survey, ART, Retention, Access, Africa, HIV, AIDS
* Correspondence: julieambia@gmail.com
1London School of Hygiene and Tropical Medicine, London, UK
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Ambia et al. BMC Health Services Research  (2017) 17:758 
DOI 10.1186/s12913-017-2678-1
Background
In 2015, 10.3 million people were receiving antiretroviral
therapy (ART) in Eastern and Southern Africa compared
with 4 million in 2010, accounting for 60% of the people
receiving ART globally [1]. This number is expected to
increase further following revisions to the ART eligibility
criteria in the 2015 World Health Organisation (WHO)
guidelines that recommend treatment initiation for every-
one who is HIV-infected, regardless of their immunological
status (dubbed “universal test and treat”) [2]. Implementing
these new guidelines will be an essential step towards
achieving the UNAIDS “90–90-90” target (i.e. by 2020, 90%
of HIV-infected people will be diagnosed, 90% of the indi-
viduals diagnosed will receive sustained ART and 90% of
the individuals on ART will achieve viral suppression) in
order to eliminate AIDS by 2030 [1].
A recent systematic review of studies published between
2008 and 2013 reported that almost a quarter of adult pa-
tients in sub-Saharan Africa (SSA) were lost to follow-up
(LTFU) within one year of starting ART [3] clearly chal-
lenging attainment of these ambitious targets. Various
health systems factors have been cited as barriers to reten-
tion in care including repeated stock-outs of ART, lack of
on-site CD4 testing, prolonged delays before receiving
viral load results, and long waiting times for consultations
[4, 5]. The 2015 WHO guidance included different ap-
proaches intended to improve access and retention in
HIV care and treatment programmes. However the rate at
which countries adopt and subsequently implement these
guidelines varies. For instance, it took an average of
24 months for most countries to adopt the 2010 WHO
ART guidelines [6]. Between December 2013 and May
2015, Kenya, Uganda, Tanzania, Malawi, Zimbabwe and
South Africa revised their national ART guidelines to
make them consistent with the 2013 WHO guidelines on
treatment eligibility [7]. In these countries, the time-
period between publication of the 2013 WHO guidelines
on treatment eligibility (i.e. June 2013) and the revision of
national ART guidelines averaged 12 months (range 6–
23 months).
Understanding the implementation of the WHO 2013
guidance on the use of antiretroviral drugs for treating
and preventing HIV infection at the health facility level
will help to identify existing gaps in HIV service provision.
Addressing these gaps is likely to be an important step in
ensuring health systems readiness for the implementation
of future HIV policies including those on universal “test
and treat”. In this study, we assess the adoption of the
2013 WHO HIV treatment and prevention recommen-
dations into national guidelines in six African countries
between 2013 and 2016. We additionally describe progress
in the implementation of national policies on ART ac-
cess and retention within the health facilities serving
the populations of rural health and demographic
surveillance sites (HDSS) in each country over the
same time-period.
Methods
Policy review
We updated a previous policy review conducted by Church
et al., [8] in which national HIV policies published between
January 2003 and June 2013 were documented in six
sub-Saharan African countries. The focus of the updated
policy review was to assess the uptake of the 2013 WHO
recommendations related to the eligibility threshold for
ART initiation, the availability of first-line ART regimes,
and recommendations to improve retention. Internet
searches were conducted to obtain national guidelines,
addendums to the national ART guidelines, and clinical
guidelines for the management of ART patients published
between July 2013 and July 2015.
Health facility survey
We surveyed health facilities located within or on the border
of ten HDSS in Kenya (Nairobi and Kisumu), Malawi
(Karonga), South Africa (Agincourt and uMkhanyakude),
Tanzania (Ifakara and Kisesa), Uganda (Masaka and Rakai)
and Zimbabwe (Manicaland) (Fig. 1). These HDSS are part
of the network for Analysing Population-based HIV/AIDS
data on Africa (ALPHA) [9] and conduct population-based
HIV surveillance in eastern and southern Africa (http://
alpha.lshtm.ac.uk/). All facilities serving the population of
the HDSS sites were sampled except in Nairobi, where a
convenience sample was selected and in Ifakara, where only
facilities with more than 100 ART patients were included.
Cross-sectional health facility surveys were conducted
between 2013 and 2015 (mostly 2013–2014) (round 1)
and between 2015 and 2016 (round 2). At the time of
round 1, all countries were using the 2010 WHO HIV
prevention and treatment guidelines on ART eligibility,
except Uganda where the 2013 WHO guidelines were
already in place. By round 2, all countries had adopted
the 2013 WHO guidelines.
Face-to-face interviews were conducted in English
with the staff manager (in small facilities) or the person
managing ART services (in large facilities) using a struc-
tured questionnaire. The design of the questionnaire has
been described elsewhere [10]. Briefly, a conceptual frame-
work that included five thematic areas and 54 corre-
sponding indicators derived from a systematic review of
literature, WHO guidelines and expert reviews informed
the content of the questionnaire. Within the five thematic
areas, we selected 12 indicators pertaining to ART access
and eight indicators on ART retention (see Table 1).
Data management and analysis
Data from Nairobi, Karonga, Agincourt, Umkhanyakude,
Masaka, Rakai, Kisesa and Ifakara were entered into an
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MS SQL Server (Microsoft Corp) database in Nairobi.
Data from Kisumu and Manicaland, were collected on
tablets using software developed using the Open Data
Kit (ODK) platform (https://opendatakit.org/), and merged
with data from the other institutions. Cleaning, mer-
ging and analysis of the datasets was carried out using
Stata 14 [11].
Descriptive statistics were used to compare selected
indicators in each country across the two rounds. The
results are presented as the percentage of facilities that
reported adherence to each of the indicators in round 1
and 2. Median numbers (with interquartile range (IQR))
were obtained for continuous variables.
Results
National-level policy adoption
Seven policy documents were published between July
2013 and July 2015. We identified one policy document
from Kenya [12], Malawi [13], Tanzania [14], Uganda
[15], Zimbabwe [16] and two from South Africa [17, 18].
All countries had some explicit policies that aimed to
increase ART access in line with the WHO 2013 guide-
lines on ARTaccess and retention in care (see Additional file 1).
Kenya, Malawi, South Africa, Tanzania, Uganda and
Zimbabwe had adopted policies on decentralisation and
nurse-led ART initiation prior to the WHO recommen-
dations. However, no national policy mentioned that lay
cadres could distribute ART in the community. Only
Malawi’s policies indicated that a three-month supply
of ART should be given to clinically stable patients.
Policy implementation
In total, 145 facilities were included in the analysis, with
data collected in both round 1 (2013 to 2015) and round
2 (2015 to 2016). The time between round 1 and round
2 averaged 20.9 months (range 16–25 months). Nineteen
facilities were excluded (four from Kenya, five from South
Africa, two from Tanzania, and eight from Uganda) be-
cause they were not surveyed in both rounds.
Health facility characteristics
The majority of facilities were either small health centres
or dispensaries (75% in round 1 and 82% round 2) and
81% were government owned in both rounds (Table 2).
All facilities had a median of three full-time nurses or
midwives (IQR: 1.0–5.0 in round 1 and IQR: 2.0–5.5 in
round 2) providing HIV services. The proportion of fa-
cilities having doctors or clinical officers providing ser-
vices was 36% in round 1 and 46% in round 2. In
round 1, Kenya had the highest median number of
weekly ART patients seen per health care worker (11
(IQR: 5–17)) and Malawi had the lowest (1 (IQR: 0–1)). In
round 2, South Africa had the highest median number of
weekly ART patients seen per health care worker (21
(IQR: 11–44) and again Malawi had the lowest (0 (IQR:
0–2)). In most facilities the caseloads were <50 ART
Fig. 1 Location of the health and demographic surveillance systems
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patients/nurse or clinician per week, with only one facility
in South Africa in round 2 reporting caseloads of >100
ART patients/nurse or clinician per week.
Service access and coverage
Across all countries 97% of the facilities in round 1 and
96% in round 2 were providing ART free of charge to all
patients. In Malawi, all facilities in both rounds had
nurses initiating ART. In other sites, the proportion of
facilities with nurses initiating ART increased between
round 1 and 2 from 76% to 93% in Kenya, and 67 to
100% in Zimbabwe, with smaller changes in Tanzania
(60 to 80%), Uganda (79 to 83%) and South Africa (96
and 96%).
Quality of care
All facilities in South Africa and Tanzania (in both
rounds) reported that they had an HIV treatment and
prevention guideline (for any year) (Table 3). The propor-
tion of facilities that had HIV treatment and prevention
guidelines increased in Kenya (87 to 100%), and Zimbabwe
(40 to 80%), with smaller changes in Malawi (60 to 80%)
and Uganda (84 to 100%).
In both rounds, 75% of facilities indicated that at least
one staff member had received training on ART. Almost
all facilities received supervisory visits at least once a
year in both rounds: Malawi (80 to 100%), South Africa
(91 to 100%), Uganda (95 to 100%) Kenya (95 to 98%),
Zimbabwe (100 to 94%) and Tanzania (93 and 93%).
No facilities in Malawi and Zimbabwe reported stock-
outs of first-line ART in round 2 (from 20 and 7% re-
spectively in round 1). In other countries, stock-outs
were still apparent with little change seen in the propor-
tion of facilites that experienced first-line ART stock-out
in the past year between round 1 and 2 (Kenya: 18 to
8%, Uganda: 16 to 17%, South Africa: (13 and 13%) and
Tanzania: (33 and 33%). Similarly, the overall proportion
of facilities reporting stock-outs of regimens containing
tenofovir (TDF) with efavirenz (EFV) was similar between
round 1 and 2 (18% in round 1 and 11% in round 2).
The proportion of facilites that were stocked with iso-
niazid preventive therapy (IPT) increased from 58 to
93% in Kenya and from 87 to 100% in South Africa, but
showed little change in other countries: Uganda (0 to
11%), Malawi (100 to 80%), Zimbabwe (53 to 43%) and
Tanzania (13 and 13%). All facilities in Kenya, Malawi,
and Uganda had stocked co-trimoxazole (CTX) in round
Table 1 Selected ART access and retention indicators
Policies Themes in the conceptual framework Indicators
ART access Service access and coverage Proportion of facilities providing ART at no cost
Proportion of facilities allowing clinical officers and nurses or midwives to initiate ART
Quality of care Proportion of facilities providing ART training and refresher courses regularly to health
care workers
Proportion of facilities conducting supervisory visits regularly
Median number of nurses providing HIV care
Proportion of facilities with reliable stock levels of ART in the past year
Proportion of facilities with reliable stock levels of isoniazid preventive therapy (IPT) in
the past year
Medical management Proportion of facilities requiring no laboratory tests before ART initiation
Proportion of facilities using WHO ART eligibility threshold as the standard for initiating ART
Proportion of facilities providing IPT to ART patients
Proportion of facilities conducting tuberculosis (TB) screening at every visit
Proportion of facilities providing WHO recommended first-line ART regimen
Retention in care Coordination of care and patient
tracking
Proportion of facilities integrating TB and HIV services
Proportion of facilities providing three month ART refills
Proportion of facilities conducting pill count in every visit
Support to people living with HIV Proportion of facilities conducting home visits or making calls or sending text messages
to patients with suboptimal adherence
Proportion of facilities conducting home visit or making calls or sending text messages
to patients who have missed their visits
Proportion of facilities encouraging ART patients to join a peer support group
Proportion of facilities encouraging ART patients to enrol for home based care
Proportion of facilities providing dietary supplements to undernourished patients
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1 and 2, with similarly high proportions in South Africa
(91 to 96%) and Zimbabwe (92 to 97%). Tanzania had the
lowest proprotion of facilities stocking CTX (60 to 40%).
Medical management
All facilities providing ART services reported a median
increase in the patient load from 32 (IQR: 7–60) in
round 1 to 36 (IQR: 10–84) in round 2. Taking the de-
nominator as the number of HIV positive patients who
enrolled in the clinic, we estimated the proportion who
initiated ART within three months. In Malawi, the pro-
portion increased from 53% in round 1 to 90% in round
2, while in all other countries the proportion was un-
changed with 70 to 83% of all enrolled HIV positive pa-
tients initiating ART within three months (see Fig. 2).
In Tanzania and Malawi, 100% of facilities reported
that ART intiation occurred within 2 weeks among pa-
tients co-infected with tuberculosis (TB) in round 2
(Tanzania: from 80% in round 1; Malawi: from 80% in
round 1). Zimbabwe and Kenya both reported 100% im-
plementation in round 1 with a reduction in round 2 to
91 and 85%, respectively. In Uganda and South Africa,
there was little change across rounds the (79 to 89%)
and (96 and 96%), respectively.
Positive changes were noted in the proportion of facil-
ities that were starting patients on ART after three or
more adherence counselling sessions between round 1
and round 2 in Kenya (13 to 35%), South Africa (48 to
83%), Tanzania (33 to 100%) and Zimbabwe (13 to
100%). Implementation in Uganda remained constant
and low (21 to 22%). In both rounds, all facilities in
Malawi were starting patients on ART during their first
or second visit. Malawi is the only country that did not
require a laboratory test before ART initiation in both
round 1 and 2. Overall, the proportion of facilities in the
other countries providing same-day ART initiation
remained low in both round 1 (5%) and 2 (8%).
The percentage of facilities initiating ART patients with
a CD4 count of 500 cells/μL or less rose between round 1
and 2 from 0 to 55% in Kenya, 0 to 80% in Malawi, 53 to
91% in South Africa, 0 to 83% in Uganda and 7 to 83% in
Zimbabwe. However, this proportion remained the same
(6.7%) in Tanzania over the corresponding period as most
facilities were initiating patients with a CD4 count of 250
cells/μL or less. Overall, the proportion increased from 12
to 68% between round 1 and 2 in all facilities.
Only Uganda and Zimbabwe had complete informa-
tion on the CD4 counts of patients at ART initiation.
Little change was noted in ART initiation amongst
PLHIV with a CD4 count of less than 200 cells/μL be-
tween round 1 and round 2 in Uganda (26 to 23%) and
Zimbabwe (53 to 57%) nor for ART initiation with CD4
count below 350 cells/μL between round 1 and 2 in
Uganda (65 and 66%) and Zimbabwe (90 to 100%).
Nearly all facilities (96% in round 1 and 99% in round
2) were providing CTX prophylaxis to ART patients in
both rounds. TB screening of patients at every visit was
reportedly carried out by 94% of the health facilities in
round 1 and 96% of the health facilities in round 2. The
proportion of facilities providing IPT between round 1
and 2 increased from 76 to 95% in Kenya, but there was
little change in South Africa (96 to 100%), Tanzania (13
to 20%) and Malawi (100 to 80%). Overall, the proportion
of facilities that provided IPT increased from 58 to 71%.
First-line ART regimens
The proportion of facilities that prescribed the first-line
ART regimen (TDF with EFV) recommended in the
Fig. 2 Overall proportion of patients initiating ART within three months of enrolment at clinic, by country for each round
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2013 WHO guidelines rose between round 1 and 2 in all
countries (Fig. 3). This was universally implemented in
Malawi in both rounds. In round 1, six facilities in
Zimbabwe were still prescribing d4T-based regimens.
However, this dropped to one facility in round 2.
Retention in care
Coordination of care and patient tracking
Integration of HIV and TB services was implemented in
all facilities in South Africa and Zimbabwe in both
rounds. There were no signficant changes in the propor-
tion of facilites that integrated HIV and TB services be-
tween round 1 and 2 in all other countries, with all
except Malawi reporting near 90% implementation
(Uganda: 78 to 89%, Kenya: 100 to 95%, Tanzania: 93
and 93% and Malawi: 60 and 60%).
There was an overall increase in the proportion of fa-
cilities that provided two-month supplies of ART (30 to
49%). However, the proportion remained similarly low in
both round 1 (43%) and round 2 (38%) for three-month
supplies of ART. Over 90% of all facilities in both rounds
(95 to 93%) reportedly allowed ART pick-ups by a desig-
nated person. No facility allowed ART patients to pick-
up ART supplies in the community.
Support to people living with HIV
Table 4 shows that implementation of additional strat-
egies to support PLHIV and improve retention were high
in both rounds with few changes noted across all coun-
tries (conducting home visits and/or making phone calls
to patients who missed their clinic visit within two
weeks (89 to 96%), establishment of peer support groups
(84 to 88%), routine pill counts (74 and 74%). Similarly,
high levels of implementation were noted for the
provision of home-based care (94 to 87%), and nutritional
supplements and food packages to malnourished patients
(78 to 77%) in both round 1 and 2.
Discussion
This multi-country study has shown a rapid adoption of
the 2013 WHO HIV guidelines and significant improve-
ments in the implementation of policies to improve ac-
cess to ART and retention in care across six countries in
SSA by 2017. Our sequential cross-sectional survey
rounds between 2013/2015 and 2015/2016 suggest that
improvements in ART access have been accompanied by
the widespread distribution of suitable guidelines to the
facility level, decentralisation of services, high levels of
supervisory visits, provision of ART services free of charge,
and initiation of ART at higher CD4 counts. Additionally,
the health facilities included in the study were increasingly
practicing nurse-led ART initiation. This task-shifting
approach has been shown to increase both efficiency
and effectiveness of ART service delivery [19, 20]. Similar
improvements were noted in some strategies to improve
retention including improvements to the integration of
TB and HIV services, improved provision of sequential ad-
herence counselling sessions, allowing treatment partners
to collect medication and continued implementation of
support strategies for PLHIV.
Despite this progress, our findings suggest that chal-
lenges still remain with implementation of national pol-
icies on HIV treatment access and retention in care. For
example, although we saw high levels of implementation
of the 2013 WHO recommended first-line treatment, a
substantial proportion of facilities reported a stock-out
Fig. 3 Proportion of health facilities starting patients on different ART regimens during the last three months, by country. *KEN 1-Kenya round 1
*KEN 2-Kenya round 2 *MWI 1-Malawi round 1 *MWI 2-Malawi round 2 *ZAF 1-South Africa round 1 *ZAF 2-South Africa round 2 *TZA 1-Tanzania
round 1 *TZA 2-Tanzania round 2 *UGA 1-Uganda round 1 *UGA 2-Uganda round 2 *ZIM 1-Zimbabwe round 1 *ZIM 2-Zimbabwe round 2
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in the last three months prior to the survey providing an
ongoing cause for concern. Inconsistent stock levels
have been shown to have negative consequences on
treatment outcomes and patients’ motivations to remain
on HIV treatment [21]. Furthermore, recent qualitative
work in these HDSS sites suggests that inconsistent
stocks of ART prohibits health providers from distribut-
ing two- or three- monthly supplies of ART [22]. Longer
durations between clinic times are recommended by
WHO and Malawi national policies for clinically-stable
ART patients and may help to promote retention in care
[23]. However, we found that the proportion of facilites
providing three-month supplies of ART remained low in
both round 1 (43%) and round 2 (38%). Additional efforts
are needed to enable facilities to reduce the frequency
of clinic visits, particularly as countries will see more
“healthy” patients after the implementation of universal
test and treat policies. Spacing clinic visits for clinically
stable patients has been theorised to free up more time
for patients who need more support [23].
No facility was able to provide ART through community
outreach, despite policies allowing this in several countries
[8]. Additional research is needed to better understand the
reasons behind the slow adoption of this strategy. A study
in South Africa reported that trained health care workers
did not consider such a delivery mechanism as a viable
option, believing that the delivery of ART must be done
from clinics [24]. Given that current evidence suggests
better outcomes among patients utilising this model for
adherence support and ART refills [25, 26] and in light of
the growing numbers of patient initiating ART as coun-
tries adopt 2015 WHO guidelines, countries must develop
their own models of differentiated care to meet the local
needs.
The facilities in Tanzania showed the least change in
the implementation of policies to expand access to and
retention on ART between the two survey rounds. Fur-
thermore, we noted that a low percentage of patients ini-
tiated ART at higher CD4 counts in Tanzanian facilities
despite national adoption of the 2013 WHO guidelines
in Tanzania by 2015. It is possible that the frequency
with which the WHO treatment guidelines are updated
could act as a deterrent for the early uptake and imple-
mentation of 2013 WHO guidelines, particularly since
roll out strategies take time and resources to implement.
Furthermore, in resource-limited settings, the reliability
of drug availability remains a challenge, and at the time
of the second round, funding negotiations between the
Tanzanian government and the Global Fund to Fight
AIDS, Tuberculosis and Malaria were still ongoing [27].
Other factors such as stigma, younger age, gender norms
[28, 29] and unequal distribution of HIV treatment facil-
ities in the country [30] may have also prevented use of
ART at higher CD4 counts in the health facilities.
Study strengths and limitations
To our knowledge this is the first study to use two se-
quential cross-sectional surveys to compare implementa-
tion of policies on ART access and retention across six
African countries with a generalised HIV epidemic. This
study also had limitations that should be considered
when interpreting the findings. First, the survey was
conducted in health facilities serving HDSS sites in each
country, and thus the facilities were not selected to be
nationally representative. In three large facilities in Rakai,
Masaka and Kisumu, additional support was provided for
service delivery which could have positively affected the
quality of care in comparison to other facilities which op-
erated under typical national supervision. Second, popula-
tions within HDSS sites may be different in terms of their
treatment-seeking behaviours than those in the general
population [31] which may affect the patient volumes wit-
nessed in this study. Third, the completion of the survey
by facility managers may present reporting bias and the
results may not be a true reflection of the quality of care
offered in that facility. Fourth, although the same facilities
were used in both surveys, different personnel within the
facility may have responded to the survey questionnaire,
and any changes in the service may have local reasons
(such as personnel changes or transport disruption). Fifth,
the analysis on these data were primarily to describe
changes, and not to test the significance of any changes.
The conceptual framework that underpinned this study
was developed prior to the first facility survey round and
was based on a review of literature and policy in circula-
tion up to 2015. Whilst comprehensive at the time, the
provision of HIV care and treatment is a rapidly evolving
field and it is possible that additional indicators would
now be included. Nevertheless this analysis provides a de-
tailed overview of the implementation status of HIV access
and retention policies across 145 facilities in six sub-
Saharan African countries between 2013 and 2016, a time
when considerable changes were taking place at the policy
level.
Conclusion
As the number of people initiating or receiving ART
continues to increase, ART service delivery needs to take
into account the timeliness of ART initiation following
eligibility and enhance programme retention. Overall,
there were major improvements in adopting and imple-
menting key policies on increasing ART access and im-
proving retention in most countries. The remaining areas
for potential improvement relate to allowing lay cadres to
distribute ART in the communities where ART patients
live and minimising ART stock-outs. Addressing this area
could improve retention among patients now taking ART
for longer periods.
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